Canagliflozin approved for type 2 diabetes

被引：2
|
作者：
Traynor, Kate
机构：
来源：
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY | 2013年 / 70卷 / 10期
关键词：
D O I：
10.2146/news130035
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
下载
收藏
页码：834 / 834
页数：1
相关论文
共 50 条
  • [31] Pharmacokinetics and pharmacodynamics of canagliflozin in pediatric patients with type 2 diabetes
    Tamborlane, William V.
    Polidori, David
    Argenti, Domenick
    Di Prospero, Nicholas A.
    PEDIATRIC DIABETES, 2018, 19 (04) : 649 - 655
  • [32] Review of approved pioglitazone combinations for type 2 diabetes
    Forst, Thomas
    Hanefeld, Markolf
    Pfuetzner, Andreas
    EXPERT OPINION ON PHARMACOTHERAPY, 2011, 12 (10) : 1571 - 1584
  • [33] The treatment of type 1 diabetes mellitus with agents approved for type 2 diabetes mellitus
    Munir, Kashif M.
    Davis, Stephen N.
    EXPERT OPINION ON PHARMACOTHERAPY, 2015, 16 (15) : 2331 - 2341
  • [34] Effects of Canagliflozin on Cardiovascular Biomarkers in Older Adults With Type 2 Diabetes
    Januzzi, James L.
    Butler, Javed
    Jarolim, Petr
    Sattar, Naveed
    Vijapurkar, Ujjwala
    Desai, Mehul
    Davies, Michael J.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 70 (06) : 704 - 712
  • [35] Canagliflozin monotherapy: clinical study data in type 2 diabetes mellitus
    Matthaei, S.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 : S59 - S64
  • [36] Canagliflozin reduces epicardial fat in patients with type 2 diabetes mellitus
    Shusuke Yagi
    Yukina Hirata
    Takayuki Ise
    Kenya Kusunose
    Hirotsugu Yamada
    Daiju Fukuda
    Hotimah Masdan Salim
    Gulinu Maimaituxun
    Susumu Nishio
    Yuriko Takagawa
    Saori Hama
    Tomomi Matsuura
    Koji Yamaguchi
    Takeshi Tobiume
    Takeshi Soeki
    Tetsuzo Wakatsuki
    Ken-ichi Aihara
    Masashi Akaike
    Michio Shimabukuro
    Masataka Sata
    Diabetology & Metabolic Syndrome, 9
  • [37] Efficacy and safety of canagliflozin in older subjects with type 2 diabetes mellitus
    Sinclair, A.
    Bode, B.
    Harris, S.
    Vijapurkar, U.
    Gassmann-Mayer, C.
    Fung, A.
    Shaw, W.
    Usiskin, K.
    Desai, M.
    Meininger, G.
    DIABETOLOGIA, 2013, 56 : S383 - S383
  • [38] Effect of canagliflozin on liver function tests in patients with type 2 diabetes
    Leiter, L. A.
    Forst, T.
    Polidori, D.
    Balis, D. A.
    Xie, J.
    Sha, S.
    DIABETES & METABOLISM, 2016, 42 (01) : 25 - 32
  • [39] Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
    David R. Matthews
    Qiang Li
    Vlado Perkovic
    Kenneth W. Mahaffey
    Dick de Zeeuw
    Greg Fulcher
    Mehul Desai
    William R. Hiatt
    Mark Nehler
    Elisa Fabbrini
    Mary Kavalam
    Mary Lee
    Bruce Neal
    Diabetologia, 2019, 62 : 926 - 938
  • [40] Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
    Li, JingWei
    Woodward, Mark
    Perkovic, Vlado
    Figtree, Gemma A.
    Heerspink, Hiddo J. L.
    Mahaffey, Kenneth W.
    de Zeeuw, Dick
    Vercruysse, Frank
    Shaw, Wayne
    Matthews, David R.
    Neal, Bruce
    JACC-HEART FAILURE, 2020, 8 (01) : 57 - 66
12345